search
Back to results

Delayed Start to Ovarian Stimulation (DOS/DOR)

Primary Purpose

Diminished Ovarian Reserve, Infertility, In Vitro Fertilization

Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Ganirelix acetate
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diminished Ovarian Reserve focused on measuring DOR, Infertility, IVF, ART, GnRHa, GnRH Antagonist Protocol, Ganirelix

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Antral Follicle Count (AFC) less than or equal to 4 as measured by transvaginal ultrasound (TVUS), or
  • Cancellation of a prior IVF cycle due to poor ovarian response.
  • Patients will receive an antagonist stimulation protocol for IVF, or IVF with Intracytoplasmic Sperm Injection (ICSI).

Exclusion Criteria:

  • Severe male factor infertility requiring surgical intervention to obtain sperm
  • Major uterine abnormality,
  • Preimplantation genetic diagnostic (PGD) testing,
  • Planned cycles without embryo transfer (for example, freeze-all, donor, or surrogate cycles).

Sites / Locations

  • UCSF Center for Reproductive Health

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Delayed Start

Conventional Start

Arm Description

Study subjects will receive 7 days of pre-treatment with a GnRH antagonist (Delayed Start) before standard ovarian stimulation with FSH/LH.

Ovarian stimulation with standard antagonist protocols (no delay).

Outcomes

Primary Outcome Measures

Fertilization Proportions
Developmental competence (fertilization of oocytes) through standard in vitro fertilization (estimated time frame to be between 8-24 hours following IVF). This percentage will be calculated as the number of fertilized eggs ( 2PN stage) per total number of eggs collected from the egg retrieval.
Number of Oocytes Retrieved
The egg retrieval procedure will be performed 36 hours after the ovulation trigger. The procedure is estimated to take up to 1 hour at study visit as part of routine care. The number of retrieved eggs will be counted

Secondary Outcome Measures

Embryo Quality
Embryo quality will be assessed by the embryologist on days 2 or 3 (Cleavage stage) following IVF using standard embryo grading criteria. Embryos grading is based on three criteria: the number of blastomere cells present in the embryo, the degree of observed cell fragmentation and the degree of observed symmetry of the cells.
Pregnancy Rates
Beta HCG levels will be assessed at 2 weeks and 3 weeks after embryo transfer. A positive pregnancy is defined as two positive beta HCG levels (a value > 5 mIU/ml ) observed over the time frame.
Stages of Oocyte Nuclear Maturation
Quality of oocytes will be assessed for developmental stages (Germinal Vesicles, Meiosis I, or Meiosis II)
Number of Mature Follicles
Maturation of follicles will be assessed by measuring the size of follicles (mature > 13mm) prior to (or at the time of) oocytes retrieval.
Oocyte Recovery Rate
The number of oocytes recovered at the time of oocyte retrieval following ovarian stimulation.

Full Information

First Posted
May 2, 2012
Last Updated
May 20, 2021
Sponsor
University of California, San Francisco
Collaborators
Merck Sharp & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT01614067
Brief Title
Delayed Start to Ovarian Stimulation
Acronym
DOS/DOR
Official Title
Delayed Start to Ovarian Stimulation Improves Oocyte Maturation and Quality: A Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Terminated
Why Stopped
Slow enrollment resulted in withdraw of funding
Study Start Date
May 2012 (undefined)
Primary Completion Date
July 2014 (Actual)
Study Completion Date
September 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
Merck Sharp & Dohme LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
In couples with infertility secondary to Diminished Ovarian Reserve, the investigators hypothesize that a delayed start (7 day) to ovarian stimulation with an GnRH antagonist (Ganirelix) will improve oocyte maturation and quality, and improve pregnancy outcomes.
Detailed Description
Over the past two decades, the success rate of assisted reproductive technology (ART) has dramatically increased. This increase is attributed to improvements in embryo culture, laboratory conditions, and optimization of ovarian stimulation protocols. Over the past years, there has been more interest in altering the ovarian stimulation protocol to improve outcomes. For example, recently our group found that a modification of ovulation trigger toward a more physiologic process improves oocyte quality and pregnancy outcomes. Others have suggested minimal stimulation improves in vitro fertilization (IVF) outcomes. The investigators propose to further investigate modifying the ovarian stimulation for women who have "decreased" ovarian reserve. The investigators propose that a delayed start to ovarian stimulation will improve oocyte maturation and quality and pregnancy outcomes. No published studies to date have evaluated if a delayed start to ovarian stimulation improves pregnancy outcomes. However, the investigators hypothesize that the use an antagonist for a delayed start of stimulation will work by one of two mechanisms: I. The partial suppression of FSH will allow for further recruitment of early antral follicles. II. The partial suppression of FSH will allow for further FSH responsiveness in existing follicles to synchronize the primary cohort, thereby increasing the total number of follicles.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diminished Ovarian Reserve, Infertility, In Vitro Fertilization
Keywords
DOR, Infertility, IVF, ART, GnRHa, GnRH Antagonist Protocol, Ganirelix

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Delayed Start
Arm Type
Experimental
Arm Description
Study subjects will receive 7 days of pre-treatment with a GnRH antagonist (Delayed Start) before standard ovarian stimulation with FSH/LH.
Arm Title
Conventional Start
Arm Type
Active Comparator
Arm Description
Ovarian stimulation with standard antagonist protocols (no delay).
Intervention Type
Drug
Intervention Name(s)
Ganirelix acetate
Other Intervention Name(s)
Ganirelix
Intervention Description
Subjects will receive 7 days of pre-treatment with the GnRH antagonist
Primary Outcome Measure Information:
Title
Fertilization Proportions
Description
Developmental competence (fertilization of oocytes) through standard in vitro fertilization (estimated time frame to be between 8-24 hours following IVF). This percentage will be calculated as the number of fertilized eggs ( 2PN stage) per total number of eggs collected from the egg retrieval.
Time Frame
8 to 24 hours after in vitro fertilization, oocytes will be checked for fertilization
Title
Number of Oocytes Retrieved
Description
The egg retrieval procedure will be performed 36 hours after the ovulation trigger. The procedure is estimated to take up to 1 hour at study visit as part of routine care. The number of retrieved eggs will be counted
Time Frame
up to 1 hour after oocytes retrieved
Secondary Outcome Measure Information:
Title
Embryo Quality
Description
Embryo quality will be assessed by the embryologist on days 2 or 3 (Cleavage stage) following IVF using standard embryo grading criteria. Embryos grading is based on three criteria: the number of blastomere cells present in the embryo, the degree of observed cell fragmentation and the degree of observed symmetry of the cells.
Time Frame
One hour on day 2 or 3 (following IVF procedure)
Title
Pregnancy Rates
Description
Beta HCG levels will be assessed at 2 weeks and 3 weeks after embryo transfer. A positive pregnancy is defined as two positive beta HCG levels (a value > 5 mIU/ml ) observed over the time frame.
Time Frame
2 to 3 weeks following embryo transfer
Title
Stages of Oocyte Nuclear Maturation
Description
Quality of oocytes will be assessed for developmental stages (Germinal Vesicles, Meiosis I, or Meiosis II)
Time Frame
average of 1 to 2 hours on the Day of Retrieval
Title
Number of Mature Follicles
Description
Maturation of follicles will be assessed by measuring the size of follicles (mature > 13mm) prior to (or at the time of) oocytes retrieval.
Time Frame
up to 1 hour (during the Transvaginal Ultrasound before Retrieval of Oocytes)
Title
Oocyte Recovery Rate
Description
The number of oocytes recovered at the time of oocyte retrieval following ovarian stimulation.
Time Frame
up to 1 hours after oocyte retrieval

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Antral Follicle Count (AFC) less than or equal to 4 as measured by transvaginal ultrasound (TVUS), or Cancellation of a prior IVF cycle due to poor ovarian response. Patients will receive an antagonist stimulation protocol for IVF, or IVF with Intracytoplasmic Sperm Injection (ICSI). Exclusion Criteria: Severe male factor infertility requiring surgical intervention to obtain sperm Major uterine abnormality, Preimplantation genetic diagnostic (PGD) testing, Planned cycles without embryo transfer (for example, freeze-all, donor, or surrogate cycles).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mitchell Rosen, MD
Organizational Affiliation
UCSF Center for Reproductive Health and Fertility Preservation
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCSF Center for Reproductive Health
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
21300334
Citation
Blockeel C, Riva A, De Vos M, Haentjens P, Devroey P. Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm injection treatment cycle: impact on ovarian stimulation. A pilot study. Fertil Steril. 2011 Apr;95(5):1714-9.e1-2. doi: 10.1016/j.fertnstert.2011.01.028.
Results Reference
background

Learn more about this trial

Delayed Start to Ovarian Stimulation

We'll reach out to this number within 24 hrs